Antineoplastic Agents, Hormonal

"Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Descriptor ID	D018931
MeSH Number(s)	D27.505.954.248.169
Concept/Terms	Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Hormonal Agents, Antineoplastic Hormonal Antineoplastic Agents Hormonal Antineoplastics Antineoplastic Hormonal Drugs Drugs, Antineoplastic Hormonal Hormonal Drugs, Antineoplastic Hormonal Antineoplastic Drugs Antineoplastics, Hormonal Antineoplastic Hormonal Agents Agents, Antineoplastic Hormonal Antineoplastic Drugs, Hormonal

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Hormonal".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antineoplastic Agents, Hormonal [D27.505.954.248.169]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Agents, Hormonal".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Hormonal".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in this website by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publications.

Bar chart showing 105 publications over 24 distinct years, with a maximum of 11 publications in 2005 and 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	2	2
1998	1	0	1
1999	1	0	1
2002	0	2	2
2003	4	4	8
2004	2	4	6
2005	7	4	11
2006	2	1	3
2007	1	3	4
2008	4	2	6
2009	1	2	3
2010	2	3	5
2011	3	8	11
2012	4	2	6
2013	5	2	7
2014	0	1	1
2015	3	4	7
2016	1	2	3
2017	2	0	2
2018	5	1	6
2019	3	2	5
2020	1	0	1
2021	1	1	2
2022	0	2	2

Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles.

Cobain EF, Hayes DF. Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Clin Oncol. 2022 11 10; 40(32):3673-3676.

View in: PubMed
Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga RC, Ahmed I, Doos L, Thornber S, Taylor KJ, Brachtel EF, Pirrie SJ, Schnabel CA, Rea DW. Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study. Clin Cancer Res. 2022 May 02; 28(9):1871-1880.

View in: PubMed
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021 12 16; 385(25):2336-2347.

View in: PubMed
Paoletti C, Barlow WE, Cobain EF, Bergqvist M, Mehta RS, Gralow JR, Hortobagyi GN, Albain KS, Pusztai L, Sharma P, Godwin AK, Thompson AM, Hayes DF, Rae JM. Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. Clin Cancer Res. 2021 11 15; 27(22):6115-6123.

View in: PubMed
Wagner LI, Gray RJ, Sparano JA, Whelan TJ, Garcia SF, Yanez B, Tevaarwerk AJ, Carlos RC, Albain KS, Olson JA, Goetz MP, Pritchard KI, Hayes DF, Geyer CE, Dees EC, McCaskill-Stevens WJ, Minasian LM, Sledge GW, Cella D. Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. J Clin Oncol. 2020 06 10; 38(17):1875-1886.

View in: PubMed
Hayes DF, Rae JM. Pharmacogenomics and Endocrine Therapy in Breast Cancer. J Clin Oncol. 2020 02 20; 38(6):525-528.

View in: PubMed
Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Ahmed I, Piper T, Salunga R, Brachtel EF, Pirrie SJ, Schnabel CA, Rea DW. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. Ann Oncol. 2019 11 01; 30(11):1776-1783.

View in: PubMed
Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med. 2019 06 20; 380(25):2395-2405.

View in: PubMed
Sheng JY, Blackford AL, Bardia A, Venkat R, Rosson G, Giles J, Hayes DF, Jeter SC, Zhang Z, Hayden J, Nguyen A, Storniolo AM, Tarpinian K, Henry NL, Stearns V. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy. Breast Cancer Res Treat. 2019 Aug; 176(3):617-624.

View in: PubMed
Kadakia KC, Kidwell KM, Barton DL, Schott AF, Hayes DF, Griggs JJ, Henry NL. Factors influencing the use of extended adjuvant endocrine therapy. Breast Cancer Res Treat. 2019 May; 175(1):181-189.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement